2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-165180
    Lyso-sulfatide (bovine) sodium 70005-46-8 98%
    Lyso-sulfatide (bovine) sodium is a phospholipid component derived from sphingolipid catabolism and a potent factor Xa inhibitor and anticoagulant. Lyso-sulfatide (bovine) sodium binds directly to factor Xa and inhibits prothrombin activation mediated by the prothrombinase complex, thereby prolonging factor Xa-induced plasma clotting time and suppressing thrombin generation. Lyso-sulfatide (bovine) sodium serves as a reliable lipid membrane mimic for studying cell membrane structure, function, and molecular interactions.
    Lyso-sulfatide (bovine) sodium
  • HY-165341
    SCR1693 1442559-20-7 98%
    SCR1693 is a selective, reversible, orally active and noncompetitive inhibitor of AChE (IC50 = 0.68 μM) as well as a calcium channel blocker. SCR1693 reduces tau phosphorylation levels, and inhibits the generation and release of Aβ. SCR1693 restores insulin signaling and improves cognitive deficits. SCR1693 can be used for the study of Alzheimer's disease, especially which complicated with type 2 diabetes mellitus.
    SCR1693
  • HY-165498
    AU-461 220854-06-8
    AU-461 is an orally active and reversible inhibitor of the gastric H⁺/K⁺ ATPase with IC₅₀ values for rabbit-derived and pig-derived enzymes are 12.15 μM and 4.20 μM respectively. AU-461 competes with activated cationic K⁺ (Kᵢ = 1.64 μM). AU-461 reduces both histamine-stimulated gastric acid secretion and basal gastric acid secretion in rats. AU-461 inhibits ulcer formation caused by ethanol or sodium hydroxide, and restores the plasma gastrin level to normal. AU-461 can be used for the study of peptic ulcers.
    AU-461
  • HY-167262
    AGN-191659 156691-86-0 98%
    AGN-191659 is an orally active RAR/RXR agonist with EC50 values of 11 nM, 23 nM, and 37 nM for RXRα, RARβ, and RARγ, respectively. AGN-191659 activates RXRα, RARβ and RARγ to induce gene transcription. AGN-191659 induces tissue transglutaminase activity, inhibits ornithine decarboxylase activity induced by tumor promoters, and suppresses chondrogenesis. AGN-191659 reverses basic fibroblast growth factor-induced endothelial cell proliferation. AGN-191659 induces hypertriglyceridemia in rat models. AGN-191659 inhibits total heparin-releasable lipase activity. AGN-191659 can be used in research related to promyelocytic leukemia and hypertriglyceridemia.
    AGN-191659
  • HY-16743C
    Ibiglustat hydrochloride 1629063-79-1 98%
    Ibiglustat hydrochloride is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat hydrochloride can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease.
    Ibiglustat hydrochloride
  • HY-167467
    Allochenodeoxycholic acid 15357-34-3
    Allochenodeoxycholic acid is a nucleoside metabolite.
    Allochenodeoxycholic acid
  • HY-167639
    (S)-Ramosetron 132036-90-9 98%
    (S)-Ramosetron ((S)-YM060 free base) is an orally active antagonist of the 5-hydroxytryptamine 5-HT3 receptor. (S)-Ramosetron is promising for research of diseases related to nausea and vomiting, irritable bowel syndrome (IBS).
    (S)-Ramosetron
  • HY-167711
    Sirtuin modulator 9 863589-28-0 98%
    Sirtuin modulator 9 (Compound 214) is a sirtuin-modulating compound that may be used to increase lifespan of cells and in diseases related to aging, inflammation and cancer as well as diseases that would benefit from increased mitochondrial activity.
    Sirtuin modulator 9
  • HY-167717
    (Rac)-Eflucimibe 191791-65-8 98%
    (Rac)-Eflucimibe ((Rac)-F 12511) is an ACAT inhibitor with endogenous hypercholesterolemia modulating activity. (Rac)-Eflucimibe has shown high potency and efficacy as an anti-hypercholesterol compound in different hypercholesterolemia animal models.
    (Rac)-Eflucimibe
  • HY-167770
    Chrysin 7-sulfate 863992-13-6
    Chrysin 7-sulfate is a conjugated metabolite of Chrysin (HY-14589). Chrysin 7-sulfate can strongly displace the Site I marker warfarin from human serum albumin. Chrysin 7-sulfate can effectively displace Ochratoxin A (OTA) (HY-N6788) from albumin both in vitro and in vivo.
    Chrysin 7-sulfate
  • HY-16781S
    Grapiprant-d4
    Grapiprant-d4 (CJ-023423-d4) is the deuterium labeled Grapiprant (HY-16781). Grapiprant (CJ-023423) is a selective EP4 receptor antagonist whose physiological ligand is prostaglandin E2 (PGE2). Grapiprant displaces [3H]-PGE2 (1 nM) binding to dog recombinant EP4 receptor with IC50 value of 35 nM and Ki value of 24 nM. Grapiprant has the potential for osteoarthritic pain and inflammation treatment[3] .
    Grapiprant-d4
  • HY-167917
    Conjugated linoleic acid 121250-47-3
    Conjugated linoleic acid is a group of isomers of Linoleic acid (HY-N0729) containing conjugated double bonds. Conjugated linoleic acid is mainly derived from dairy products and ruminant meats. Conjugated linoleic acid exhibits various activities such as anti-carcinogenicity, immunomodulation, weight loss promotion, reduction of muscle damage, and alleviation of inflammatory responses. Conjugated linoleic acid can be used as a food additive.
    Conjugated linoleic acid
  • HY-167931
    Cinnamohydrazide 3538-69-0 98%
    Cinnamohydrazide, an unsaturated carboxylic acid derivative, serves as a precursor to aspartame through enzyme-mediated amination to phenylalanine. This compound may offer potential benefits in the prevention and treatment of diabetes by facilitating insulin secretion, enhancing pancreatic β-cell function, inhibiting hepatic gluconeogenesis, promoting glucose uptake, amplifying insulin signaling pathways, delaying carbohydrate digestion and glucose absorption, and reducing protein glycation and insulin fibrillation.
    Cinnamohydrazide
  • HY-168074
    4″-C18 EGCG 98%
    4″-C18 EGCG is a potent inhibitor of α-amylase and α-glucosidase with IC50 values of 3.74 and 0.81 μM, respectively. 4″-C18 EGCG inhibits carbohydrate hydrolases, reduces oxidative stress and inflammation, and exhibits antidiabetic activity. 4″-C18 EGCG also downregulates proinflammatory cytokines and is cytotoxic to primary human peripheral blood mononuclear cells (PBMCs), non-cancer cell lines 3T3-L1, and HEK 293 at 50 μM.
    4″-C18 EGCG
  • HY-168168
    (5aS,6R,6aR)-MK-8666 1544739-76-5 98%
    (5aS,6R,6aR)-MK-8666 is a selective GPR40 agonist with activity in promoting fatty acid-induced insulin secretion in pancreatic β cells and intestinal enteroendocrine cells. (5aS,6R,6aR)-MK-8666 has been studied for the inhibition of type 2 diabetes and has shown significant blood glucose lowering effects. Although (5aS,6R,6aR)-MK-8666 is considered to have potential inhibitory advantages, its development was stopped in Phase I clinical trials due to liver safety issues.
    (5aS,6R,6aR)-MK-8666
  • HY-168185
    α-glucosidase/PTP1B-IN-1 98%
    α-glucosidase/PTP1B-IN-1 (compound 8a) is a potent α-glucosidase and PTP1B inhibitor with an IC50 value of 66.3 μM and 47.0 μM, respectively. α-glucosidase/PTP1B-IN-1 exhibits excellent activities against α-amylase with an IC50 of 30.62 μM. α-glucosidase/PTP1B-IN-1 can dock into the active pockets of α-glucosidase and PTP1B. α-glucosidase/PTP1B-IN-1 has potential to reduce the postprandial blood glucose and is used for Type 2 diabetes mellitus.
    α-glucosidase/PTP1B-IN-1
  • HY-168329
    TGR5 agonist 7 98%
    TGR5 agonist 7 (Compound 22-Na) is a gut-restricted, orally active agonist for G protein-coupled bile acid receptor TGR5 (GPBAR1 or GPR131) with an EC50 < 1 μM. TGR5 agonist 7 exhibits blood glucose lowering effect in mouse model, and can be used in diabete research.
    TGR5 agonist 7
  • HY-168332
    FXR agonist 11 2768502-17-4 98%
    FXR agonist 11 (Compound 14) is an FXR agonist with an EC50 of 1.2 μM and a maximum effect of 73.7%. FXR agonist 11 can significantly increase GSH levels in the liver and is used to study drug-induced liver injury diseases.
    FXR agonist 11
  • HY-168371
    1-Palmitoyl-2-13(S)-HODE-sn-glycero-3-PC 161923-56-4 98%
    1-Palmitoyl-2-13(S)-HODE-sn-glycero-3-PC (13-HODE-PC) is an oxidized phospholipid that contains Palmitic acid (HY-N0830) and 13(S)-HODE (HY-113884B) at the sn-1 and sn-2 positions, respectively. 1-Palmitoyl-2-13(S)-HODE-sn-glycero-3-PC has the ability to compete for the binding of 125I-NO2-LDL (5 g/mL) to CD36-transfected 293 cells, with the IC50 of ＞ 200 μM.
    1-Palmitoyl-2-13(S)-HODE-sn-glycero-3-PC
  • HY-168372
    1-Myristoyl-2-Linoleoyl-sn-glycero-3-PC 92345-33-0 98%
    1-Myristoyl-2-Linoleoyl-sn-glycero-3-PC is a phospholipid that contains Myristic acid (HY-N2041) and Linoleic acid (HY-N0729) at the sn-1 and sn-2 positions, respectively, which is found in human plasma.
    1-Myristoyl-2-Linoleoyl-sn-glycero-3-PC
Cat. No. Product Name / Synonyms Application Reactivity